These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 19850525)

  • 1. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
    Hacke W; Kaste M; Fieschi C; von Kummer R; Davalos A; Meier D; Larrue V; Bluhmki E; Davis S; Donnan G; Schneider D; Diez-Tejedor E; Trouillas P
    Lancet; 1998 Oct; 352(9136):1245-51. PubMed ID: 9788453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR.
    Ahmed N; Wahlgren N; Grond M; Hennerici M; Lees KR; Mikulik R; Parsons M; Roine RO; Toni D; Ringleb P;
    Lancet Neurol; 2010 Sep; 9(9):866-74. PubMed ID: 20667790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
    Zinkstok SM; Roos YB;
    Lancet; 2012 Aug; 380(9843):731-7. PubMed ID: 22748820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
    Wahlgren N; Ahmed N; Dávalos A; Hacke W; Millán M; Muir K; Roine RO; Toni D; Lees KR;
    Lancet; 2008 Oct; 372(9646):1303-9. PubMed ID: 18790527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteplase: new indication. Inadequately assessed in ischaemic stroke.
    Prescrire Int; 2004 Aug; 13(72):127-31. PubMed ID: 15532135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
    Goyal M; Menon BK; van Zwam WH; Dippel DW; Mitchell PJ; Demchuk AM; Dávalos A; Majoie CB; van der Lugt A; de Miquel MA; Donnan GA; Roos YB; Bonafe A; Jahan R; Diener HC; van den Berg LA; Levy EI; Berkhemer OA; Pereira VM; Rempel J; Millán M; Davis SM; Roy D; Thornton J; Román LS; Ribó M; Beumer D; Stouch B; Brown S; Campbell BC; van Oostenbrugge RJ; Saver JL; Hill MD; Jovin TG;
    Lancet; 2016 Apr; 387(10029):1723-31. PubMed ID: 26898852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Muir KW; Ford GA; Ford I; Wardlaw JM; McConnachie A; Greenlaw N; Mair G; Sprigg N; Price CI; MacLeod MJ; Dima S; Venter M; Zhang L; O'Brien E; Sanyal R; Reid J; Sztriha LK; Haider S; Whiteley WN; Kennedy J; Perry R; Lakshmanan S; Chakrabarti A; Hassan A; Marigold R; Raghunathan S; Sims D; Bhandari M; Wiggam I; Rashed K; Douglass C;
    Lancet Neurol; 2024 Nov; 23(11):1087-1096. PubMed ID: 39424558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.